Sjoerd A.M.E.G. Timmermans

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

Alexander P. J. Vlaar, Sanne de Bruin, Matthias H. Busch et al. · The Lancet Rheumatology · 2020 · 200 citations · Full text

Life Sciences, Immunology, Infectious Diseases +8

Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities

Sjoerd A.M.E.G. Timmermans, Myrurgia A. Abdul‐Hamid, Joris Vanderlocht et al. · Kidney International · 2017 · 145 citations · Full text

Medicine, Hematology, Internal Medicine +13

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Alexander P. J. Vlaar, Martin Witzenrath, Pieter van Paassen et al. · The Lancet Respiratory Medicine · 2022 · 142 citations · Full text

Medicine, Infectious Diseases, Pharmacotherapy +12

C5b9 Formation on Endothelial Cells Reflects Complement Defects among Patients with Renal Thrombotic Microangiopathy and Severe Hypertension

Sjoerd A.M.E.G. Timmermans, Myrurgia A. Abdul‐Hamid, Judith Potjewijd et al. · Journal of the American Society of Nephrology · 2018 · 96 citations · Full text

Medicine, Nephrology, Pathology +17

Diagnostic and Risk Factors for Complement Defects in Hypertensive Emergency and Thrombotic Microangiopathy

Sjoerd A.M.E.G. Timmermans, Alexis Wérion, Jan Damoiseaux et al. · Hypertension · 2019 · 73 citations · Full text

Medicine, Nephrology, Pathobiology +17